US BANCORP \DE\ - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.

Quarter-by-quarter ownership
US BANCORP \DE\ ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$232,651
-29.8%
6,526
-9.2%
0.00%
-100.0%
Q2 2023$331,629
+211.8%
7,189
+171.1%
0.00%
Q1 2023$106,345
-24.1%
2,652
-12.3%
0.00%
Q4 2022$140,055
-60.1%
3,023
-64.4%
0.00%
-100.0%
Q3 2022$351,000
-29.1%
8,481
+2.4%
0.00%0.0%
Q2 2022$495,000
-20.8%
8,281
-3.8%
0.00%0.0%
Q1 2022$625,000
-1.0%
8,611
+14.6%
0.00%0.0%
Q4 2021$631,000
-57.5%
7,514
-54.4%
0.00%
-66.7%
Q3 2021$1,485,000
-1.2%
16,479
+4.5%
0.00%0.0%
Q2 2021$1,503,000
-33.3%
15,763
-20.4%
0.00%
-40.0%
Q1 2021$2,254,000
+9.0%
19,793
+32.5%
0.01%
+25.0%
Q4 2020$2,067,000
+497.4%
14,935
+253.9%
0.00%
+300.0%
Q3 2020$346,000
+3744.4%
4,220
+3771.6%
0.00%
Q2 2020$9,000
+350.0%
109
+131.9%
0.00%
Q1 2020$2,0000.0%470.0%0.00%
Q4 2019$2,000
-50.0%
47
-54.4%
0.00%
Q3 2019$4,000
-63.6%
103
-38.3%
0.00%
Q2 2019$11,0000.0%1670.0%0.00%
Q1 2019$11,000
+266.7%
167
+169.4%
0.00%
Q4 2018$3,000
-70.0%
62
-53.4%
0.00%
Q3 2018$10,0000.0%1330.0%0.00%
Q2 2018$10,000
+150.0%
133
+64.2%
0.00%
Q1 2018$4,000
+300.0%
81
+237.5%
0.00%
Q4 2017$1,00024
+700.0%
0.00%
Q3 2017$0
-100.0%
3
-97.6%
0.00%
Q1 2017$8,000
-11.1%
125
-3.1%
0.00%
Q4 2016$9,000
-73.5%
129
-81.4%
0.00%
Q2 2016$34,000
+9.7%
693
+43.5%
0.00%
Q1 2016$31,000
-70.2%
483
-47.7%
0.00%
Q4 2015$104,000
+25.3%
924
+7.4%
0.00%
Q3 2015$83,000
-2.4%
860
+2.6%
0.00%
Q2 2015$85,0008380.00%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q4 2020
NameSharesValueWeighting ↓
First Light Asset Management, LLC 213,887$29,608,0002.19%
Rock Springs Capital Management LP 566,500$78,421,0001.66%
FEDERATED HERMES, INC. 4,280,528$592,554,0001.21%
AtonRa Partners 17,646$2,443,0001.20%
EMERALD MUTUAL FUND ADVISERS TRUST 218,390$30,232,0001.05%
EMERALD ADVISERS, LLC 226,875$31,406,0001.04%
Atika Capital Management LLC 89,000$12,319,0000.96%
Capital Impact Advisors, LLC 25,582$3,541,0000.87%
JGP Global Gestao de Recursos Ltda. 1,586$220,0000.83%
CAPITAL INTERNATIONAL LTD /CA/ 79,742$11,039,0000.64%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders